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Abstract
Purpose As epidermal growth factor receptor (EGFR) inhib-
itors are associated with a variety of dermatologic adverse
events (dAEs), the purpose of this study was to develop an
overview of current knowledge of dAEs associated with
EGFR inhibitors and to identify knowledge gaps regarding
incidence, treatment, impact on quality of life (QOL), and
patient acceptance.
Method A structured literature search was conducted using
MEDLINE/PubMed (January 1983 to January 2014). In total,
71 publications published from 2004 to 2014 were identified
for consideration in the final evidence review.
Results The majority of published articles concentrate on the
incidence of skin reactions, duration, treatment, and prevention
strategies. Different grading systems based on the symptoms of
skin rash or on health-related QOL (HRQOL) are used. An
additional topic is the possible correlation between acneiform
rash and efficacy of EGFR inhibitors. Knowledge gaps identi-
fied in the literature were how dAEs impact QOL compared
with other AEs from a patient’s perspective, patients’ accep-
tance of dAEs (willingness to tolerate), and the impact of
physician-patient communication on treatment decisions.
Conclusions Research is needed on the impact of dAEs on
patients’ acceptance of cancer treatments. Systematic studies
are missing that compare the impact of dAEs with other tox-
icities on therapy decisions from both physician’s and pa-
tient’s view, and that investigate the balance between efficacy
and avoidance of acneiform rash in treatment decisions. Such
studies could provide deeper insights into the acceptance of
the risk of untoward dermatologic events by both physicians
and patients when treating advanced cancers.
Keywords Dermatologic adverse events . EGFR
inhibitors . Health-related quality of life . Skin rash
Introduction
In recent years, several agents have been developed that
inhibit the epidermal growth factor receptor (EGFR), which
plays a central role in growth of certain cancers. Monoclonal
antibodies (mAbs; e.g., cetuximab, panitumumab,
necitumumab) and tyrosine kinase inhibitors (TKIs; e.g.,
erlotinib, gefitinib, lapatinib, afatinib) blocking different
EGFR targets are therefore an indispensable part of cancer
treatment. EGFR inhibitors are used to treat advanced or
metastatic non-small cell lung cancer (afatinib, erlotinib,
gefitinib, necitumumab), pancreatic cancer (erlotinib),
breast cancer (lapatinib), colon cancer (cetuximab,
panitumumab), and head and neck cancer (cetuximab).
Compared with cytotoxic chemotherapy with taxanes,
Electronic supplementary material The online version of this article
(doi:10.1007/s00520-016-3419-4) contains supplementary material,
which is available to authorized users.








1 Kantar Health, Munich, Germany
2 Merck KGgA, Darmstadt, Germany
3 Dermatology Service, Department of Medicine, Memorial Sloan
Kettering Cancer Center, 1275 York Avenue, New York, NY 10065,
USA
Support Care Cancer (2017) 25:651–660
DOI 10.1007/s00520-016-3419-4
fluoropyrimidines, and platinum compounds that are
known to be associated with multiple adverse events
(AEs) such as fatigue, pain, nausea and emesis, hemato-
logic toxicity, and neuropathy, EGFR inhibitors may have
a lower impact on health-related quality of life (HRQOL).
However, due to the role of EGFR in skin biology, all
EGFR inhibitors are associated with a variety of derma-
tologic AEs (dAEs), e.g., acneiform (papulopustular) rash,
hair changes (hair loss, facial hypertrichosis, eyelash
trichomegaly), pruritus, mucositis, xerosis and fissures,
and paronychia (Fig. 1).
Due to increased incidence of dAEs associated with
targeted cancer therapies, a large volume of publications have
focused on these toxicities. To get an overview of the current
research status and to identify knowledge gaps, this article
summarizes the main findings on this topic. It is noteworthy
that the severity of patients’ AEs, including those of the skin
[1], does not necessarily correlate with the amount to which
patients are actually distressed. This requires a special focus
on patient-reported outcomes and patients’ HRQOL as part of
this literature analysis.
Methods
In the first step, a structured literature search was conducted
with the aim of collecting all published articles containing
information on ≥1 of the following topics: (1) types of skin
toxicities and incidences, (2) toxicity grading systems, (3)
prevention and treatment strategies, (4) correlation of rash
and efficacy of anti-EGFR therapies, (5) impact of rash on
QOL/patient-reported outcomes, and (6) patient acceptance
of dAEs/patient adherence.
The literature search was conducted using MEDLINE/
PubMed (1st January 1983 to 31st January 2014). MEDLINE
contained 17,024,638 articles published during this time period.
In addition, further articles were identified by manually
searching the references of articles obtained through the elec-
tronic search. The search was performed using keywords com-
bined with appropriate operators (AND, OR): (1) skin toxicity
(OR skin rash, exanthema, acneiform eruption, dermatology,
skin disease) AND (2) EGFR inhibitors (OR anti-EGFR,
cancer therapy, monoclonal antibodies, tyrosine kinase
inhibitors, TKIs, cetuximab, Erbitux, panitumumab, Vectibix,
erlotinib, Tarceva, gefitinib, Iressa, lapatinib, Tykerb, Tyverb,
necitumumab, afatinib, Giotrif, Gilotrif, trametinib, Mekinist,
pertuzumab, Jevtana) AND (3) patient acceptance (OR
patient-related outcome, patient tolerance, patient reactions, pa-
tient compliance, patient adherence, patient persistence, treat-
ment discontinuation, treatment persistence, dose reduction,
interrupted treatment, therapy decision, quality of life, QOL,
utility assessment, risk-benefit balance). In total, 71 publica-
tions (including 10 reviews, guidelines, and recommendations;
60 research studies; and 1 book) published from 2004 to 2014
were identified for consideration in the final evidence review.
Results
Due to the availability of data from clinical studies (interven-
tional as well as non-interventional), the majority of published
articles concentrate on the incidence of different dAEs, on
treatment and prevention strategies, and on the putative corre-
lation between dAEs and efficacy. Based on the growing
knowledge about incidence of skin toxicities, further topics
appear in recent publications that are more patient oriented:
the impact on QOL and the development of grading systems
to assess this impact through patient-reported outcomes and
questionnaires. Only a small number of publications refer to
patient acceptance of dAEs or to patient adherence to therapies
associated with dAEs.
Here, we concentrate on the major findings for each topic,
with a more detailed focus on patient-reported outcomes and
patients’ HRQOL. Other findings are summarized elsewhere
in more detail [2–6].
Incidence of dermatologic adverse events
Skin rash/acneiform rash is the most frequently observed
dAE associated with EGFR inhibitors and can be observed
in the majority of patients treated with mAbs (Table 1).
Other prominent dAEs induced by EGFR inhibitors are
xerosis, pruritus, nail changes, mucositis, fissures of fin-
gertips and toes, and hair changes [3–16]. It has been
A B CFig. 1 Dermatologic adverse
events associated with EGFR
inhibitors: a paronychia, b
xerosis, and c acneiform rash
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claimed that severe dAEs may result in significant physi-
cal and emotional discomfort [15]. However, the incidence
of these toxicities alone does not allow drawing conclu-
sions on their impact on QOL. Based on the reported high
incidence of dAEs, the authors conclude that dermatologic
toxicities associated with EGFR inhibitors underscore the
importance of dermatologic evaluation, prevention, and
treatment of these toxicities [17].
Grading systems for skin rash
Accurate grading of papulopustular rash associated with
anti-EGFR therapy is essential to ensure timely and ap-
propriate intervent ions. Current ly, the Common
Terminology Criteria for Adverse Events (CTCAE) is a
widely used classification system in clinical trials. The
most recent version (version 4.03) of this tool was pub-
lished in June 2010 [18, 19]. For example, severe skin
rash (grade 3) is defined by papules and/or pustules
covering ≥30 % of the body surface area, limited self-
care activities of daily living, or associated local superin-
fection (oral antibiotics indicated). Grade 2 skin rash is
described to be Bassociated with psychosocial impact,^
but a validated tool to assess the degree of psychosocial
impact is not part of the CTCAE. In addition, the CTCAE
scale does not separately characterize the specific derma-
tologic toxicities observed with EGFR inhibitor therapy
(xerosis, pruritus, paronychia, hair abnormalities, and
mucositis).
In addition to the CTCAE, several alternative EGFR
inhibitor- focused grading systems for dAEs have been
proposed in recent years [2, 20–22]. Although several
scaling systems exist, no studies have investigated how
much these tools are actually used. In particular, it is not
known how often current diagnosis of dAEs systematical-
ly includes assessment of restrictions in daily and social
activities, emotional stress, and the need for dermatologic
treatment.
Table 1 Overview of dermatologic adverse events in patients with cancer treated with EGFR inhibitors [4, 5, 12, 14, 33, 74]











All grades 80 49 10 16 Alopecia: 5 <1
Grade 3/4 10 4 1 <1 Trichomegaly: 12 <1
Panitumumab
All grades 77 46 63 25 6
Grade 3/4 4 0 2 2 Trichomegaly: 6 <1
Necitumumab
All grades 65 24 21 N/A N/A N/A
Grade 3/4 3 7 0 N/A N/A N/A
TKIs
Afatinib
All grades 73 15 16 34
Grade 3/4 13 <1 <1 4
Erlotinib
All grades 75 12 13 14 Alopecia: 6 19
Grade 3/4 9 0 <1 <1 Trichomegaly: 11 <1
Gefitinib
All grades 47 11 8 3 – 2
Grade 3/4 2 0 <1 <1 – 1
Lapatinib
All grades 47 13 12 11 Alopecia: 13 44
Grade 3/4 3 <1 <1 <1 0
Overall
All grades 47–100 10–49 8–57 3–25 Alopecia: 0–13 0–44
Grade 3/4 1–10 0–7 0–2 0–2 Trichomegaly: 0–12 0–1
Reported rates are derived from different studies in various diseases, combinations, and different durations of treatment
EGFR epidermal growth factor receptor, mAb monoclonal antibody, N/A not available, TKI tyrosine kinase inhibitor
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Prevention and treatment strategies
Much of the literature about EGFR inhibitor-induced skin
toxicities contains prevention and treatment recommendations
[1, 2, 7, 12, 15, 23–29]. Based on the recommendations of the
Multinational Association for Supportive Care in Cancer Skin
Toxicity Study Group, clear guidelines for prevention and
treatment have been developed, e.g., for skin rash (prevention:
hydrocortisone, minocycline; treatment: alclometasone,
fluocinonide, clindamycin, doxycycline, minocycline, isotret-
inoin), radiation-induced dermatitis, pruritus, oral complica-
tions, xerosis and fissures, and paronychia. The clinical prac-
tice guidelines are summarized in detail elsewhere [15].
However, no studies have investigated how often patients with
cancer treated with EGFR inhibitors actually receive a preven-
tive treatment, the criteria used to determine whether patients
receive a preventive treatment, and how much dermatologists
are involved in treatment recommendations [30].
Correlation of skin rash and efficacy of anti-EGFR
therapies
Moreover, numerous studies confirmed that skin rash (the
frequently occurring type of dAE caused by EGFR inhibitors)
is associated or correlated with efficacy of the EGFR inhibitor
therapy [2, 8, 9, 13, 20, 24, 29–52]. Efficacy measures inves-
tigated in such studies are usually response rate or overall
survival (OS), e.g., by comparing response rates or median
OS between subgroups of patients with no rash, grade 1 rash,
and grade ≥2 rash. However, the findings do not allow the
conclusion that the therapy is not effective if no or only mild
dAEs occur. In addition, it is not known whether patients with
an advanced stage of cancer actually prefer a cancer therapy
with a high risk of severe skin rash even though the therapy
does not cure the disease in the majority of cases.
Impact of skin rash on quality of life/patient-reported
outcomes
Eleven surveys (2007–2013) that report results on the impact
of skin rash on HRQOL were identified and analyzed. Ten
surveys report a negative impact onHRQOL, particularly with
higher grades of skin rash (grade ≥2) [38, 53–61]. Only one
author reports no correlation of grade of skin toxicity with
QOL regarding the difference in QOL between patients with
skin rash grade 0/1 vs grade ≥2 [47]. However, this study used
the EQ-5D to assess QOL, and the EQ-5D is a general QOL
measure that is not tailored to measure QOL related to skin
conditions.
To assess HRQOL, different tools are available as follows:
Skindex-16 [38, 62], Skindex-29 [62], Functional Assessment
of Cancer Therapy (FACT)-EGFRI-18 [54], DIELH [60],
Dermatology Life Quality Index (DLQI) [56, 63], and general
assessments of QOL through HRQL [64] or EQ-5D [47].
The two Skindex questionnaires (1 with 16 items, 1 with 29
items) measure comprehensively the effects of skin disease on
different dimensions of HRQOL: symptoms (e.g., itching,
burning sensations), emotions (e.g., frustration, embarrass-
ment, feeling depressed), and functions (e.g., effect on rela-
tionships, daily activities, and work). Skindex-16 is a brief
version (one-page questionnaire) assessing not only how often
patients have a particular experience but also how much
they are bothered by it. Each question asks the patient to
quantify how much a specific aspect of his or her skin
condition bothered him or her in the week prior to admin-
istration of the questionnaire. The overall score can be
further divided into three subscales: the patient’s emotion-
al state, symptom severity, and functioning state. All pub-
lished studies using Skindex reported a lower QOL for
patients with papulopustular rash. The correlation is based
on the concordance between QOL score and graded se-
verity using CTCAE: the higher the graded severity of
rash, the lower the reported QOL. The impact is highest
on the emotional dimension [38]. Furthermore, QOL is
affected more in younger patients aged <50 years.
Targeted therapies associated with dAEs are also more
often associated with a lower QOL than non-targeted ther-
apies [58], again with strongest expression in the emo-
tions domain.
Studies using scales other than Skindex to measure
HRQOL support the hypothesis of the negative impact of
dAEs on QOL as well, but with smaller sample sizes. For
example, one study using DLQI [56] identified 4 out of 16
patients with skin rash grade ≥2, and all reported a mod-
erate to strong impact on QOL. Finally, FACT-EGFR-18 is
a validated instrument with18 items, including subscales
for physical well-being (e.g., BMy skin or scalp itches^),
social/emotional well-being (e.g., BMy skin condition af-
fects my mood^; BI avoid going out in public because of
how my skin looks^), and functional well-being (e.g., BMy
skin condition interferes with my ability to sleep^) [54]. A
small sample with 10 patients treated with EGFR inhibi-
tors showed significant correlations between intensity of
dAEs and QOL.
Although the results clearly support the assumption that the
QOL of patients with cancer is affected by the occurrence of
dAEs induced by EGFR inhibitors (in particular, skin rash
grade ≥2), the sample sizes in the current literature are rather
small, and the use of these tools is currently not part of stan-
dard clinical practice. The results mainly provide insights on
how the emotional and social dimensions of life are affected
by physical conditions, but no conclusions can be drawn re-
garding whether patients and/or physicians are less motivated
to use cancer therapies causing both (severe) dAEs and wors-
ened psychosocial well-being.
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Patient acceptance of skin toxicities/patient adherence
Only a few publications report on patient acceptance of dAEs
caused by EGFR therapies [5, 56, 65–69]. Most of the studies
provide data about the frequency of dose reductions or therapy
terminations due to skin toxicities. The rate of dose reductions
or treatment terminations can be interpreted as an indicator of
low patient adherence and probably also as an indicator of low
patient acceptance. In five surveys on erlotinib, dose reduc-
tions in 11 to 17 % of patients were necessary due to skin
toxicities; 4 to 14 % of patients terminated the treatment
(Table 2).
Across all studies, treatment was interrupted by the patients
mainly because of grade ≥3 toxicities, but there are no pub-
lished data clarifying whether the decision was made by the
patients or the physicians. In a large study including 427 pa-
tients treated with erlotinib [67], 12 % of patients required
dose reductions to 100 mg daily because of drug-related rash,
and 14 % required treatment interruptions because of rash.
Nine percent of the total erlotinib group had grade ≥3 rash.
According to this study, treatment modification was not rec-
ommended for grade 1 or 2 rash [67]. For grade 3 rash, treat-
ment was withheld, the rash was treated symptomatically, and
erlotinib was restarted at a dose of 100 mg daily when the rash
was grade ≤1.
Only one study assessed patient concerns about dAEs during
treatment irrespective of dose modifications or terminations
[56]. In this retrospective survey, 16 patients treated with
EGFR inhibitors were asked whether, at some time during the
treatment, they had wanted to stop treatment for dermatologic
reasons. Three patients answered positively. Two of them had
experienced grade ≥3 dAEs, justifying treatment discontinua-
tion according to the clinical grade. One patient, however,
wanted to stop EGFR inhibitors because of the severe psycho-
logical impact of facial skin and hair modifications despite
moderate clinical grading of these changes. None of the 13
remaining patients wanted to stop therapy because of cutaneous
toxicities, including four patients with grade 3 dAEs who
stopped treatment following medical advice because of severe
dAEs. In total, in 6 of the 16 patients (37 %), EGFR inhibitors
had been temporarily discontinued: three patients on cetuximab
(grade 3 folliculitis), two patients on erlotinib (one with grade 3
folliculitis, one with atypical rash and paronychia), and one on
panitumumab (painful digital fissures). Although the survey
included a rather small number of patients (n = 16), the results
showed that some patients considered stopping therapy even
though they did not actually stop, and some patients did not
consider stopping therapy even though they did stop on the
advice of healthcare professionals.
Considering the few studies addressing low patient adher-
ence, it is clear that patient acceptance of skin toxicities is only
indirectly addressed by studies investigating dose modifica-
tions or treatment discontinuations due to AEs. High-grade
skin toxicity leads to treatment interruption and dose reduc-
tion. Data on dose adjustments are usually assessed as a part of
clinical trials (not as primary endpoints), but the incidence of
dose adjustments cannot be equated with low patient accep-
tance of AEs because more patients may be psychologically
distressed than indicated by the number whose dose was
changed or who terminated treatment.
Discussion
This literature survey clearly demonstrates that there is abun-
dant information about the incidence of dAEs caused by
EGFR inhibitors (>70 % all grades; 9–10 % grade 3; higher
incidence in mABs than in TKIs). Accordingly, prevention
and treatment of skin toxicities is an important topic in clinical
practice, at least at the level of treatment guidelines. Based on
correlation studies, the occurrence and the severity of dAEs
are associated with higher response rates and a survival ben-
efit, but dAEs are also associated with lower HRQOL, partic-
ularly for severe skin rash. Several tools are available that can
be used to measure HRQOL in patients treated with EGFR
inhibitors, but it is unclear to what extent these tools are actu-
ally used. The incidence of dose reductions and treatment
terminations due to dAEs (mainly skin rash) support the








interruption, % of patients
Shepherd et al. (2005) BR.21 study [67] Erlotinib 427 12 100 14
Tiseo et al. (2009) Italian EAP [68] Erlotinib 651 19a 50–100 4a
Reck et al. (2010) TRUST study [66] Erlotinib 6580 11 100 5





Yeo et al. (2010) [69] Erlotinib 7 100 25 N/A
EAP expanded-access program, EGFR epidermal growth factor receptor, EGFRI epidermal growth factor receptor inhibitor, N/A not available
a Dose reductions or treatment termination due to all adverse events (no separate value for skin rash available)
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hypothesis that the dAEs that occur exceed a threshold of
acceptance. However, the data are often unplanned by-
products of larger clinical trials that are focused on response
rates, progression-free survival, or OS as primary endpoints.
Of 70 publications on skin toxicities associated with the use
of EGFR inhibitors, there is only one study (with only 16 pa-
tients) that directly addresses patient concerns about dAEs dur-
ing treatment [56]. The available tools used for grading dAEs
and assessing their impact on QOL refer mainly to the severity
of reported dAEs and their impact on emotional, social, or
functional aspects of QOL. However, they do not reflect how
patients actually think about dAEs, how patients evaluate these
events compared with other AEs caused by cancer therapies,
and to what extent these events are accepted in relation to the
efficacy of cancer therapies. In addition, the available data do
not provide any insights on the physician-patient interaction
before, during, or after drug treatment. In clinical practice,
balancing different benefits and disadvantages of treatment op-
tions occurs every day when treatment decisions are made, and
the opinions of both healthcare practitioners and patients need
to be considered. Therefore, we conclude that the next genera-
tion of research projects on dAEs caused by cancer therapies
should address missing information regarding the following
issues: (1) lack of patient voice, (2) physician-patient commu-
nication regarding dAEs, (3) acceptance of (severe) skin toxic-
ities compared with other AEs, and (4) balancing the risk of
(severe) skin toxicities and the efficacy of the therapy.
(1) Overcome the issue of the missing patient voice To
better understand patients’ beliefs regarding dAEs, future
studies on dAEs should assess the experiences and opinions
of patients with cancer regarding the occurrence of skin rash
or other skin toxicities during treatment. For this purpose,
FACT-EGFRI-18 was developed to assess dermatologic
symptoms associated with EGFR inhibitors. In addition, gath-
ering information through patient interviews is useful, either
retrospectively after treatment or during treatment with EGFR
inhibitors. What are patients’ first reactions when dAEs occur,
and to what extent are patients prepared by physicians for the
occurrence of dAEs? Which aspects of dAEs are most both-
ersome (e.g., itching, dry skin, skin rash on the face vs other
regions, duration of skin rash)? Do patients accept these AEs
as part of the cancer treatment?What has been done to prevent
or treat dAEs in patients treated with EGFR inhibitors?Which
activities of daily living are affected? The main benefit of
gathering this information is to find leverage points for pre-
vention and patient education, similar to patient education on
other AEs, such as alopecia, anemia, and neutropenia [7, 9, 21,
22, 31, 35, 61, 64, 70, 71].
(2) Gather information on physician-patient communica-
tion regarding dAEs Communication about skin toxicities
like skin rash includes various aspects: informing the patient
about dAEs before starting the therapy (or during therapy
decision), deciding about preventive measures, using patient
brochures (Supplemental Figure 1), communicating with the
patient when dAEs occur, and deciding about treatment of
dAEs (which includes referrals to dermatologists). In the cur-
rent publications, none of these aspects of physician-patient
communication were investigated. For example, in the phase
of patient education before starting the therapy, it is currently
unknown howmany patients treated with EGFR inhibitors are
informed about the risk of dAEs. In addition, published data
do not contain any information on how physicians explain
dAEs (for example, skin rash) to their patients: using words
like Brash,^ Bacne,^ or Bpustules^ may lead to a patient’s
incorrect understanding of this type of AEs. To what extent
are patients shown pictures to demonstrate what a skin rash
looks like? What else is said to the patient regarding dAEs,
e.g., about itching and inflammation of skin areas and whether
this is an indicator of efficacy or at least that the agent is
active? One goal of future research will be to describe in detail
what physicians tell their patients and what sticks in the minds
of the patients. Based on the results of such surveys, it would
be easier to make the current communication more effective
by emphasizing certain aspects of skin rash that are currently
not well understood by patients [42, 55, 72].
(3) Provide insights into acceptance of (severe) skin toxic-
ities compared with other AEs Because studies have focused
on dAEs, the impact of these events on QOL compared with
that of other AEs has been insufficiently investigated. The same
concern applies to patient acceptance of dAEs compared with
other AEs. Such information could be quite easily gathered, for
example, through paired-comparison methodologies, with the
patient asked to select the most bothersome AE from two op-
tions, or to select one therapy among several treatment options
that differ only regarding their AEs (e.g., severe skin rash vs
hair loss vs fatigue/tiredness vs nausea/vomiting). To get valid
results, it will be important to conduct such a survey with pa-
tients with cancer who have been treated with EGFR inhibitors
and who already experienced dAEs. Conducting the same ex-
ercise with treating physicians would provide insights about
differences between physicians’ and patients’ perception of
the burden of AEs. For example, physicians observing dAEs
with different grades among many patients might overestimate
the bothersome impact of dAEs compared with patients.
(4) Collect information on balancing the risk of (severe)
skin toxicities and the efficacy of the therapy Treatment
decisions are not made simply by selecting one therapy with
the least bothersome AE. In clinical practice, the decision
process is influenced by multiple factors, for example, tumor
histology, tumor stage, rate of progression, patient’s perfor-
mance status, patient features (e.g., age, sex, smoking status),
cancer therapies used in earlier treatment lines, clinical trial
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results of treatment options, structure of the patient samples in
clinical trials, availability of anticancer drugs, and personal
experience with the available drugs. Once a list of the most
suitable treatment options for an individual patient is deter-
mined, one option is selected based on the balance between
acceptable AEs and expected efficacy. For example, a patient
with stage IV non-small cell lung cancer could be treated in
the first line with an EGFR inhibitor (one of the available
TKIs) or with chemotherapy. The TKI is associated with a
certain risk of skin rash or other AEs (e.g., diarrhea). As the
currently approved TKIs are efficacious regarding the chance
of controlling the tumor or prolonging life for a certain num-
ber of months, the decision seems to be easy. Not accepting
the risk of severe skin rash (occurring in about 9 % of the
patients treated with oral TKIs) would mean that the patient
and the treating team of physicians would forgo the chance of
controlling the tumor. Because many patients with advanced
lung cancer are treated with TKIs (particularly when their
disease is EGFR-mutation positive), the decision between
avoiding skin rash and accepting it (with the chance of con-
trolling the disease for a certain amount of time) is obviously
toward skin rash acceptance; otherwise, patients would not be
treated with EGFR inhibitors. The psychological reasons for
this decision are probably the fact that skin rash is not life-
threatening (no case of grade 5 skin rash has been reported),
the symptoms are transitional (maximum intensity after 2 to
3 weeks, total duration until crusting of eruptions and the
phase of dry skin 5 to 8 weeks [6, 21, 72, 73]), physicians
do not describe grade 3 severe skin rash in detail, or less
informed patients associate it with juvenile acne. However,
so far, no study has been conducted that systematically inves-
tigates the balance between seeking efficacy and avoiding
severe skin rash risk. What probability of severe skin rash is
accepted at a given level of efficacy? And how to balance
tumor control with a given probability of severe skin rash?
Such studies should involve both physicians and patients with
an advanced stage of tumor development in order to compare
both groups.
Conclusion
More research is needed on the impact of dAEs on patients’
acceptance of cancer treatments. Although reduced HRQOL,
dose modifications, and therapy discontinuations have been
reported in patients with severe skin toxicity, systematic stud-
ies are missing that compare the impact of dAEs with the
impact of other toxicities on therapy decisions from both the
physician’s and patient’s view.
To overcome the issue of the rare patient voice, the next
generation of patient-related outcome studies should provide
deeper insights into how the risk of (severe) skin rash is ac-
cepted by both physicians and patients, and how efficacious a
cancer therapy should be at a given risk of severe skin rash.
Such insights might especially highlight the balance between
AEs and efficacy that needs to be achieved for a cancer drug to
be perceived as valuable by patients and physicians.
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